Navigation Links
Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis

served after Induction of Short-term Immunosuppression with Mitoxantrone Followed by Long-term Glatiramer Acetate (GA) Are Maintained at 24 Months in Patients with Relapsing Remitting Multiple Sclerosis (RRMS), determined that the increased efficacy and the safety observed at 15 months with COPAXONE(r) after brief mitoxantrone therapy was maintained with continued COPAXONE(r) at 24 months. The original study included RRMS patients (n=40), ages 18-55, who had at least one Gd-enhancing lesion at the time of the screening MRI and an Expanded Disability Status Scale (EDSS) score of ˜ 6.5. Brain MRIs were performed at screening and months six, nine, 12 and 15.

The abstract is accessible online at: http://www.abstracts2view.com/aan2007boston/view.php?nu=AAN07L_P06.096&terms <http://www.abstracts2view.com/aan2007boston/view.php?nu=AAN07L_P06.096&terms> .

Patients were randomized to receive 3 monthly intravenous (IV) infusions of mitoxantrone (36 mg/m2 total) followed by a 2-week washout, then COPAXONE(r) 20 mg/d for 12.5 months (n=21) or COPAXONE(r) 20 mg/d alone (n=19) for 15 months.

In the 24-month follow-up of continued COPAXONE(r) therapy, primary outcomes were safety and tolerability. Secondary outcomes included changes from baseline to 24 months in Gd-enhancing lesions, relapses and EDSS.

Thirty patients entered the extension study. Analyses at 15 months indicated a 70 percent reduction in Gd-enhancing lesions in the mitoxantrone-COPAXONE(r) group vs COPAXONE(r) group (risk ratio=0.30, 95 percent CI [0.11-0.86], p=0.0147). These effects appeared to be sustained.

The analysis, Reductions in Gd Enhancing Lesions Observed with Glatiramer Acetate Following a Brief and Low Dose Course of Mitoxantrone in
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Point of Care Strep Tests Speed Treatment, Lower Costs
2. Rapid HIV Testing Increases Possibility of Treatment
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
5. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
6. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
9. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
10. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
11. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
Post Your Comments:
(Date:7/31/2014)...  Decision Resources Group is launching an extension of ... now include ChinaTrack; the new capabilities track the ... dashboard providing detailed brand-level share tracking and analytics. ChinaTrack ... Other key capabilities of the new line ... to end-user surveys of healthcare facilities, ChinaTrack data is ...
(Date:7/31/2014)... BURLINGTON, Mass. , July 31, 2014 /PRNewswire/ ... committee members—who make decisions about which therapies are ... influence formulary placement, according to a new Manhattan ... Makers 2014 . The study finds that P&T ... and pharmacy benefits managers (PBMs) have set a ...
(Date:7/31/2014)... July 31, 2014 Touro University California,s College ... selected as the recipient of a $150,000 grant by ... the University to increase research and classroom space on ... technology for the study of health sciences, and will ... needs and interests of our students," said Shelley ...
Breaking Medicine Technology:Decision Resources Group Announces First Medical Device Account Targeting Tool in China 2Formulary Decision Makers Say Pharma-Provided Patient Support Solutions Influence Formulary Placement 2Formulary Decision Makers Say Pharma-Provided Patient Support Solutions Influence Formulary Placement 3Touro University California Garners Grant From Long Foundation 2
... Oct. 23 Optimer Pharmaceuticals, Inc. (Nasdaq: ... from its two fidaxomicin Phase 3 trials in patients ... 48th Annual Meeting of the Infectious Disease Society of ... oral presentation, investigator Derrick Crook, M.D., of the University ...
... 22 Amedisys, a leading home health care and hospice company ... on the future of home care in this week,s issue of ... of the Amedisys Strategic Advisory Board. Titled, "Why ... on the future of home care as an increasingly crucial component ...
Cached Medicine Technology:Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA 2Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA 3Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA 4Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA 5Media Statement From Amedisys on Dr. Steven H. Landers' NEJM Commentary on the Future of Home Care 2
(Date:7/31/2014)... Atlanta-based Jvion, a leader in clinical ... lessons in predictive population health analytics as part of ... analytics in healthcare. Ritesh Sharma, Jvion COO, commented, “it ... to understand the impact of and potential within predictive ... and a good portion of it is conflicting or ...
(Date:7/31/2014)... During the July 2014 board meeting of the ... executive director of the Mesothelioma Applied Research Foundation, Mary ... promising clinical trials to choose from than ever before. ... have been reporting increased survival and response rates. Some ... is within the field of immunotherapy. One trial, ...
(Date:7/31/2014)... ANN ARBORA new bill introduced in Congress with bipartisan ... from University of Michigan research, which could improve the ... they spend on the medicines and tests they need ... Reps. Diane Black and Earl Blumenauer, grew out of ... with the U-M,s Institute for Healthcare Policy and Innovation. ...
(Date:7/31/2014)... Jacuzzi Luxury Bath, the company ... a new and improved website to meet the needs ... Luxury Bath website has been redesigned to offer a ... represented by the company’s products. The design is current, ... bathroom applications. “The site reflects our Jacuzzi® brand standards, ...
(Date:7/31/2014)... drug, researchers at The Wistar Institute discovered that ... with fewer age-related illnesses. The mice, which lack ... degeneration, obesity, and spontaneous tumor formation when compared ... scientists view the metabolic networks within cells. ... regulator of metabolism and has been shown to ...
Breaking Medicine News(10 mins):Health News:Jvion Releases Top Three Lessons in Predictive Population Health Analytics 2Health News:Jvion Releases Top Three Lessons in Predictive Population Health Analytics 3Health News:‘More Promising Mesothelioma Clinical Trials than Ever Before,’ Says Expert 2Health News:‘More Promising Mesothelioma Clinical Trials than Ever Before,’ Says Expert 3Health News:Jacuzzi Luxury Bath Launches New and Improved Website 2Health News:'Rewired' mice show signs of longer lives with fewer age-related illnesses 2Health News:'Rewired' mice show signs of longer lives with fewer age-related illnesses 3
... planning to phase out junk food and make exercise mandatory, ... Department to counter childhood obesity//. , ,These recommendations follow ... were being sent to dieticians. , ,The NSW report, ... the biggest study of its kind in the country. The ...
... been awarded with discount shopping cards in return for ... clinic as part of the HIV/AIDS awareness program//. ... Nation's AIDS-prevention agency India has largest number of people, ... virus. ,Sushena Reza-Paul of the Karnataka Health ...
... Pradesh today in protest against dismissal of AIIMS director ... junior doctors observed a `symbolic' strike and a large ... some time condemning the sacking of Venugopal., ,Terming ... the strike was "symbolic and we have no intention ...
... Manchester is reportedly treating patients with mouth and throat cancer ... ,Sources at the Manchester cancer hospital explained that ... doctors at Christie Hospital in Didsbury, Manchester, are planning to ... clinical trail basis. They hope to try and reduce the ...
... expressed their concerns over the practice of "Breast Ironing" ... is used to stunt breast growth in girls by mothers// ... own good. ,It is aimed at warding off ... objects pressed against the developing breasts in teenaged girls. "Breast ...
... is brandishing a piece of his own skull, an ... visitors//. ,The Jawaharlal Nehru Memorial Hospital in Kalyani, ... no less visitors than any museum these days with ... getting electrocuted from a high-voltage wire, holding his own ...
Cached Medicine News:Health News:Man Holds Own Skull in Bengal Medical Miracle 2
Abdominal Binder w / Velcro...
Ideal for abdominal, flank, hip and thigh procedures....
Male high waisted compression girdle with CDIs Wonderfabric™...
This high waist tummy tuck girdle provides the same CDI Wonderfabric™ compression as the 8000 series....
Medicine Products: